Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 8/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 5/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380488 | 1.00 | P2RX3 (0.38) | P2RX3XDHPRMT5WDR77BACE1 | |
| SCHEMBL381207 | 0.96 | ELANE (0.40) | P2RX3BACE1ELANE | |
| SCHEMBL380513 | 0.96 | ELANE (0.40) | P2RX3BACE1ELANE | |
| SCHEMBL1323907 | 0.89 | P2RX3 (0.36) | P2RX3 | |
| SCHEMBL1323904 | 0.89 | P2RX3 (0.36) | P2RX3 | |
| SCHEMBL3850357 | 0.88 | MMP13 (0.41) | BACE1ELANESCN9A | |
| SCHEMBL3850352 | 0.88 | MMP13 (0.41) | BACE1ELANESCN9A | |
| SCHEMBL2212589 | 0.87 | P2RX3 (0.38) | P2RX3XDHPRMT5WDR77SCN9A | |
| SCHEMBL2211840 | 0.87 | P2RX3 (0.38) | P2RX3XDHPRMT5WDR77SCN9A | |
| SCHEMBL2209718 | 0.87 | ELANE (0.43) | P2RX3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086938-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | claimed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| EP-2086938-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008073306-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| EP-2086938-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | P2RX3 4244/4885XDH 643/4885PRMT5 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.